SuperworthLarimar Therapeutics shares outstanding LRMR
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Sep 30, 2025
- 78.3M
- On a year earlier
- +22.8%
- more shares
Larimar Therapeutics had 78.3M diluted shares outstanding on average in Q3 FY25, the quarter to Sep 30, 2025.
That is 22.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2024 | 63.8M | +45% |
| FY2023 | 43.9M | +0% |
| FY2022 | 43.9M | +139% |
| FY2021 | 18.3M | +15% |
| FY2020 | 16M | +413% |
| FY2019 | 3.1M | +1% |
| FY2018 | 3.1M | +35% |
| FY2017 | 2.3M | +1% |
| FY2016 | 2.3M | +0% |
| FY2015 | 2.3M | +20% |
| FY2014 | 1.9M | +3024% |
| FY2013 | 60.8K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q3 FY25 | 78.3M | +23% | |
| Q2 FY25 | 64M | +0% | |
| Q1 FY25 | 64M | +19% | |
| Q4 FY24 | 63.8M | +45% | |
| Q3 FY24 | 63.8M | +45% | |
| Q2 FY24 | 63.8M | +45% | |
| Q1 FY24 | 53.6M | +22% | |
| Q4 FY23 | 43.9M | +0% | |
| Q3 FY23 | 43.9M | +98% | |
| Q2 FY23 | 43.9M | +139% | |
| Q1 FY23 | 43.9M | +139% | |
| Q4 FY22 | 43.9M | +139% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Larimar Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.